Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents

Table 4

Differences in clinical outcomes between the Magmaris and Ultimaster diabetic groups.

Clinical outcomes	Magmaris DM; ()	Ultimster DM; ()	value
30-day follow-up
Primary outcome: cardiac death, myocardial infarction, and stent thrombosis	0 (0%)	2 (3.4%)
Principal secondary outcome: target lesion failure (cardiac death, target vessel myocardial infract, and target lesion revascularization)	0 (0%)	0 (0%)	—
Death
(i) Cardiac	0 (0%)	0 (0%)	—
(ii) Any	0 (0%)	0 (0%)	—
Myocardial infarction:
(i) Target vessel	0 (0%)	0 (0%)	—
(ii) Any	0 (0%)	2 (3.4%)
Scaffold: (i) Thrombosis	0 (0%)	0 (0%)	—
(ii) restenosis	0 (0%)	0	—
Revascularization:
(i) Target lesion	0 (0%)	0 (0%)	—
(ii) Target vessel	0 (0%)	0 (0%)	—
(ii) Any	0 (0%)	5 (8.5%)
1-year follow-up
Primary outcome: cardiac death, myocardial infarction, and stent thrombosis	2 (2.7%)	3 (5.1%)
Principal secondary outcome: target lesion failure (cardiac death, target vessel myocardial infract, and target lesion revascularization)	3 (4.1%)	2 (3.3%)
Death
(i) Cardiac	0(0%)	0 (0%)	—
(ii) Any	2 (2.7%)	0 (0%)
Myocardial infarction:
(i) Target vessel	2 (2.7%)	1 (1.7%)
(ii) Any	2 (2.7%)	2 (3.4%)
Scaffold:
(i) Thrombosis	0 (0%)	0 (0%)
(ii) Restenosis	2 (2.7%)	1 (1.7%)
Revascularization:
(i) Target lesion	2 (2.7%)	1 (1.7%)
(ii) Target vessel	3 (2.7%)	2 (3.4%)
(iii) Any	10 (13.8%)	10 (16.9%)